2018

  1. Graczyk-Jarzynka A, Goral A, Muchowicz A, Zagozdzon R, Winiarska M, Bajor M, Trzeciecka A, Fidyt K, Krupka JA, Cyran J, Szczygiel K, Efremov DG, Gobessi S, Jagielski A, Siudakowska K, Bobrowicz M, Klopotowska M, Barankiewicz J, Malenda A, Lech-Maranda E, Miazek-Zapala N, Skarzynski PH, Domagala A, Golab J, Firczuk M. Inhibition of thioredoxin-dependent H(2)O(2) removal sensitizes malignant B-cells to pharmacological ascorbate. Redox Biol. 2019 Feb;21:101062. doi: 10.1016/j.redox.2018.11.020. Epub 2018 Nov 29. PubMed PMID: 30576925; PubMed Central PMCID: PMC6302138.
  2. Marusiak AA, Prelowska MK, Mehlich D, Lazniewski M, Kaminska K, Gorczynski A, Korwat A, Sokolowska O, Kedzierska H, Golab J, Biernat W, Plewczynski D, Brognard J, Nowis D. Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. Oncogene. 2019 Apr;38(15):2860-2875. doi: 10.1038/s41388-018-0618-0. Epub 2018 Dec 14. PubMed PMID: 30552384; PubMed Central PMCID: PMC6484767.
  3. Kiraga Ł, Cheda Ł, Taciak B, Różańska K, Tonecka K, Szulc A, Kilian K, Górka E, Rogulski Z, Rygiel TP, Król M. Changes in hypoxia level of CT26 tumors during various stages of development and comparing different methods of hypoxia determination. PLoS One. 2018 Nov 9;13(11):e0206706. doi: 10.1371/journal.pone.0206706. eCollection 2018. PubMed PMID: 30412628; PubMed Central PMCID: PMC6226158.
  4. Bajor M, Zych AO, Graczyk-Jarzynka A, Muchowicz A, Firczuk M, Trzeciak L, Gaj P, Domagala A, Siernicka M, Zagozdzon A, Siedlecki P, Kniotek M, O'Leary PC, Golab J, Zagozdzon R. Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. Br J Cancer. 2018 Oct;119(7):873-884. doi: 10.1038/s41416-018-0263-y. Epub 2018 Oct 5. PubMed PMID: 30287919; PubMed Central PMCID: PMC6189216.
  5. Szczałuba K, Chmielewska JJ, Sokolowska O, Rydzanicz M, Szymańska K, Feleszko W, Włodarski P, Biernacka A, Murcia Pienkowski V, Walczak A, Bargeł E, Królewczyk K, Nowacka A, Stawiński P, Nowis D, Dziembowska M, Płoski R. Neurodevelopmental phenotype caused by a de novo PTPN4 single nucleotide variant disrupting protein localization in neuronal dendritic spines. Clin Genet. 2018 Dec;94(6):581-585. doi: 10.1111/cge.13450. Epub 2018 Oct 11. PubMed PMID: 30238967.
  6. Calisti L, Trabuco MC, Boffi A, Testi C, Montemiglio LC, des Georges A, Benni I, Ilari A, Taciak B, Białasek M, Rygiel T, Król M, Baiocco P, Bonamore A. Engineered ferritin for lanthanide binding. PLoS One. 2018 Aug 13;13(8):e0201859. doi: 10.1371/journal.pone.0201859. eCollection 2018. PubMed PMID: 30102720; PubMed Central PMCID: PMC6089422.
  7. Domagala A, Fidyt K, Bobrowicz M, Stachura J, Szczygiel K, Firczuk M. Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy. Int J Mol Sci. 2018 Aug 1;19(8). pii: E2256. doi: 10.3390/ijms19082256. Review. PubMed PMID: 30071644; PubMed Central PMCID: PMC6121368.
  8. Pilch Z, Tonecka K, Braniewska A, Sas Z, Skorzynski M, Boon L, Golab J, Meyaard L, Rygiel TP. Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment. Cancer Immunol Res. 2018 Aug;6(8):930-940. doi: 10.1158/2326-6066.CIR-17-0454. Epub 2018 Jul 18. PubMed PMID: 30021725.
  9. Chlebowska-Tuz J, Sokolowska O, Gaj P, Lazniewski M, Firczuk M, Borowiec K, Sas-Nowosielska H, Bajor M, Malinowska A, Muchowicz A, Ramji K, Stawinski P, Sobczak M, Pilch Z, Rodziewicz-Lurzynska A, Zajac M, Giannopoulos K, Juszczynski P, Basak GW, Plewczynski D, Ploski R, Golab J, Nowis D. Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. Haematologica. 2018 Nov;103(11):1843-1852. doi: 10.3324/haematol.2018.190231. Epub 2018 Jul 12. PubMed PMID: 30002127; PubMed Central PMCID: PMC6278960.
  10. Taciak B, Białasek M, Braniewska A, Sas Z, Sawicka P, Kiraga Ł, Rygiel T, Król M. Evaluation of phenotypic and functional stability of RAW 264.7 cell line through serial passages. PLoS One. 2018 Jun 11;13(6):e0198943. doi: 10.1371/journal.pone.0198943. eCollection 2018. PubMed PMID: 29889899; PubMed Central PMCID: PMC5995401.
  11. Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21. PubMed PMID: 29784639; PubMed Central PMCID: PMC6034642.
  12. Pyrzynska B, Dwojak M, Zerrouqi A, Morlino G, Zapala P, Miazek N, Zagozdzon A, Bojarczuk K, Bobrowicz M, Siernicka M, Machnicki MM, Gobessi S, Barankiewicz J, Lech-Maranda E, Efremov DG, Juszczynski P, Calado D, Golab J, Winiarska M. FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. Oncoimmunology. 2018 Jan 25;7(5):e1423183. doi: 10.1080/2162402X.2017.1423183. eCollection 2018. PubMed PMID: 29721381; PubMed Central PMCID: PMC5927521.
  13. Spólnicka M, Zbieć-Piekarska R, Karp M, Machnicki MM, Własiuk P, Makowska Ż, Pięta A, Gambin T, Gasperowicz P, Branicki W, Giannopoulos K, Stokłosa T, Płoski R. DNA methylation signature in blood does not predict calendar age in patients with chronic lymphocytic leukemia but may alert to the presence of disease. Forensic Sci Int Genet. 2018 May;34:e15-e17. doi: 10.1016/j.fsigen.2018.02.004. Epub 2018 Feb 7. PubMed PMID: 29472117.
  14. Domagala A, Stachura J, Gabrysiak M, Muchowicz A, Zagozdzon R, Golab J, Firczuk M. Inhibition of autophagy sensitizes cancer cells to Photofrin-based photodynamic therapy. BMC Cancer. 2018 Feb 20;18(1):210. doi: 10.1186/s12885-018-4126-y. PubMed PMID: 29463237; PubMed Central PMCID: PMC5819678.
  15. Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J. Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis. PLoS Med. 2018 Feb 20;15(2):e1002505. doi: 10.1371/journal.pmed.1002505. eCollection 2018 Feb. PubMed PMID: 29462168; PubMed Central PMCID: PMC5819765.
  16. Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang W, Palacios D, Almåsbak H, Bajor M, Clement D, Brandt L, Önfelt B, Goodridge J, Winiarska M, Zagozdzon R, Olweus J, Kyte JA, Malmberg KJ. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors. Cancer Immunol Res. 2018 Apr;6(4):467-480. doi: 10.1158/2326-6066.CIR-17-0207. Epub 2018 Feb 19. PubMed PMID: 29459477.
  17. Janyst K, Janyst M, Siernicka M, Lasek W. Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells. Oncol Rep. 2018 Apr;39(4):1999-2005. doi: 10.3892/or.2018.6248. Epub 2018 Feb 6. PubMed PMID: 29436692.
  18. Mazur M, Bartoszewicz A, Dymek B, Salamon M, Andryianau G, Kowalski M, Olejniczak S, Matyszewski K, Pluta E, Borek B, Stefaniak F, Zagozdzon A, Mazurkiewicz M, Koralewski R, Czestkowski W, Piotrowicz M, Niedziejko P, Gruza MM, Dzwonek K, Golebiowski A, Golab J, Olczak J. Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase. Bioorg Med Chem Lett. 2018 Feb 1;28(3):310-314. doi: 10.1016/j.bmcl.2017.12.047. Epub 2017 Dec 22. PubMed PMID: 29292229.
  19. Mazur M, Olczak J, Olejniczak S, Koralewski R, Czestkowski W, Jedrzejczak A, Golab J, Dzwonek K, Dymek B, Sklepkiewicz PL, Zagozdzon A, Noonan T, Mahboubi K, Conway B, Sheeler R, Beckett P, Hungerford WM, Podjarny A, Mitschler A, Cousido-Siah A, Fadel F, Golebiowski A. Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma. J Med Chem. 2018 Feb 8;61(3):695-710. doi: 10.1021/acs.jmedchem.7b01051. Epub 2018 Jan 11. PubMed PMID: 29283260.
  20. Tak T, Rygiel TP, Karnam G, Bastian OW, Boon L, Viveen M, Coenjaerts FE, Meyaard L, Koenderman L, Pillay J. Neutrophil-mediated Suppression of Influenza-induced Pathology Requires CD11b/CD18 (MAC-1). Am J Respir Cell Mol Biol. 2018 Apr;58(4):492-499. doi: 10.1165/rcmb.2017-0021OC. PubMed PMID: 29141155.
  21. Sokolowska O, Nowis D. STING Signaling in Cancer Cells: Important or Not? Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):125-132. doi: 10.1007/s00005-017-0481-7. Epub 2017 Jul 26. Review. PubMed PMID: 28748479; PubMed Central PMCID: PMC5851689.